CATB Catabasis Pharmaceuticals Inc.

2.37
+0.08  (3%)
Previous Close 2.29
Open 2.28
Price To book 2.47
Market Cap 53281712
Shares 22,481,735
Volume 632,551
Short Ratio 0.15
Av. Daily Volume 1,336,706

SEC filingsSee all SEC filings

  1. 8-K - Current report 171137139
  2. 424B5 - Prospectus [Rule 424(b)(5)] 171137124
  3. 8-K - Current report 171120395
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171021433
  5. 8-K - Current report 17917536

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a did not meet primary endpoint - June 2016
CAT-2054
Hypercholesterolemia
Phase 1/2 top-line data released January 31 - primary endpoint not met. Data from open-label presented October 4, 2017 deemed sufficient to proceed to Phase 3 development - to commence 1H 2018 with data due 2020.
Edasalonexent (CAT-1004)
Duchenne muscular dystrophy (DMD)

Latest News

  1. Corporate News Blog - Catabasis Pharma Shares Positive Results from Phase-2 MoveDMD Trials for Assessing Edasalonexent for Treatment of Duchenne Muscular Dystrophy
  2. Catabasis' DMD Candidate Slows Disease Progression, Stock Up
  3. Today's Research Reports on Trending Tickers: Catabasis Pharmaceuticals and Momenta Pharmaceuticals
  4. Evidence of Biotech Froth Continues to Mount
  5. Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 7.2% Higher
  6. Catabasis's stock rockets after positive trial results of Duchenne muscular dystrophy treatment
  7. Armed with fresh trial data, Catabasis doubles down on Duchenne drug
  8. Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD® Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial in First Half 2018
  9. Today's Research Reports on Stocks to Watch: Catabasis Pharmaceuticals and Rigel Pharmaceuticals
  10. Catabasis Pharmaceuticals to Present Results from Joint Research Collaboration with Sarepta Therapeutics at the 22nd International Congress of the World Muscle Society
  11. Catella: European Residential Properties Show Large Potential for Appreciation
  12. Catabasis Pharmaceuticals to Present Results from the Open-Label Extension of the MoveDMD® Phase 2 Trial of Edasalonexent in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society
  13. Top Ranked Momentum Stocks to Buy for September 11th
  14. Catella AB's Comments on Nasdaq Stockholm's Trading Halt for the Company's Class A-Shares
  15. Edited Transcript of CATB earnings conference call or presentation 10-Aug-17 8:30pm GMT
  16. Catabasis Pharmaceuticals posts 2Q loss
  17. Catabasis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Reviews Business Progress
  18. Investor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call
  19. Catabasis Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference
  20. Catabasis Pharmaceuticals to Report Second Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, August 10